You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 8,192,720

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,192,720

Title:	Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases
Abstract:	Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.
Inventor(s):	Kozel; Thomas (Reno, NV), Murphy; William (Reno, NV), Brandt; Suzanne (Boise, ID), Blazar; Bruce R. (Golden Valley, MN), Lovchik; Julie A. (Albuquerque, NM), Thorkildson; Peter (Reno, NV), Percival; Ann (Reno, NV), Lyons; C. Richard (Ft. Collins, CO)
Assignee:	Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno (Reno, NV) N/A (N/A)
Application Number:	12/701,149
Patent Claims:	1. A method comprising administering poly .gamma.-D-glutamic acid and a CD40 agonist to a vertebrate according to a regime such that an immune response is elicited in the vertebrate against Bacillus anthracis. 2. The method according to claim 1, wherein the CD40 agonist is an agonistic anti-CD40 antibody. 3. The method according to claim 1, wherein an administration of the CD40 agonist is simultaneous with, or separated by no more than 24 hours from, an administration of said poly .gamma.-D-glutamic acid. 4. The method according to claim 1, comprising at least one booster administration of said poly .gamma.-D-glutamic acid after an initial administration of said poly .gamma.-D-glutamic acid and the CD40 agonist. 5. The method according to claim 1, wherein said vertebrate is a human. 6. The method according to claim 1, wherein the poly .gamma.-D-glutamic acid is isolated from Bacillus anthracis. 7. The method according to claim 1, wherein the poly .gamma.-D-glutamic acid is isolated from Bacillus lichenformis. 8. The method according to claim 1, further comprising establishing an anti-.gamma.DPGA antibody producing hybridoma from the vertebrate. 9. The method according to claim 8, further comprising isolating anti-.gamma.DPGA antibodies from the hybridoma.

Details for Patent 8,192,720

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998	⤷ Try a Trial	2023-09-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.